Surgical equipment maker Teleflex raised its annual profit forecast on Thursday, banking on resilient demand for certain surgical procedures at hospitals to drive sales for its medical devices.
Get a deeper insight into the potential performance of Teleflex (TFX) for the quarter ended June 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
Teleflex (TFX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Teleflex (TFX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Investors with an interest in Medical - Instruments stocks have likely encountered both Teleflex (TFX) and SONOVA HOLDING (SONVY). But which of these two stocks presents investors with the better value opportunity right now?
Teleflex Inc TFX benefited in the first quarter from the surge in the interventional segment and other tailwinds.
Teleflex (TFX) holds strong momentum in the Interventional arm and a favorable solvency. Yet, macroeconomic impacts and competitive environment trigger concerns.
The U.S. Food and Drug Administration classified a recall of Teleflex's inflatable devices that increase blood supply to the heart muscle as "most serious".
The commercialization of Teleflex's (TFX) UroLift in Japan has been a significant step toward making this therapy more broadly available to men suffering from BPH.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.